Ibrutinib with or without ublituximab for R/R high-risk CLL

Dr. Jeff Sharman

The multicenter phase 3 GENUINE trial found that addition of the anti-CD20 monoclonal antibody ublituximab to ibrutinib for relapsed or refractory high-risk CLL resulted in statistically higher overall response rate without affecting the safety profile.